Keros Therapeutics Inc.
KROS | NASDAQ
$11.68
+$0.20 (+1.74%)
Sep 22, 2026, 12:29 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 244.06M | 3.55M | 151K | n/a | 20.1M | n/a |
Cost of Revenue | 1.51M | n/a | n/a | n/a | n/a | 605K |
Gross Profit | 242.55M | 3.55M | 151K | n/a | 20.1M | -605K |
Operating Income | 70.62M | -210.83M | -169.94M | -114.79M | -56.37M | -46.66M |
Interest Income | n/a | n/a | n/a | 1K | n/a | 6K |
Pretax Income | 91.9M | -187.05M | -152.99M | -104.68M | -56.73M | -45.53M |
Net Income | 87.01M | -187.35M | -152.99M | -104.68M | -58.74M | -45.36M |
Selling & General & Admin | 46.85M | 40.75M | 34.83M | 27.53M | 21.33M | 12.19M |
Research & Development | 129.64M | 173.63M | 135.26M | 87.27M | 55.14M | 33.86M |
Other Expenses | -4.56M | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 171.93M | 214.38M | 170.09M | 114.79M | 76.47M | 46.05M |
Interest Expense | n/a | n/a | n/a | 1K | 4K | 6K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 173.44M | 214.38M | 170.09M | 114.79M | 76.47M | 46.66M |
Income Tax Expense | 4.88M | 300K | n/a | n/a | 2.01M | -172K |
Shares Outstanding (Basic) | 37.22M | 37.44M | 29.45M | 25.24M | 23.33M | 15.51M |
Shares Outstanding (Diluted) | 37.86M | 37.44M | 29.45M | 25.24M | 23.33M | 15.51M |
EPS (Basic) | 2.34 | -5 | -5.20 | -4.15 | -2.52 | -2.93 |
EPS (Diluted) | 2.30 | -5 | -5.20 | -4.15 | -2.52 | -2.93 |
EBITDA | 93.41M | -185.82M | -152.18M | -104M | -56.35M | -44.92M |
EBIT | 91.9M | -187.05M | -152.99M | -104.68M | -56.73M | -45.53M |
Depreciation & Amortization | 1.51M | 1.23M | 815K | 674K | 378K | 605K |
Add to Watchlist
Select watchlists to add or remove KROS